Farish Fund Supports Collaboration to Study Plaques That Cause Most Heart Attacks
Aug. 14, 2013
AUSTIN, Texas — The William Stamps Farish Fund in Houston has donated $400,000 to a collaboration between the the Institute for Computational Engineering and Sciences (ICES) at The University of Texas at Austin and the Texas Heart Institute (THI) in Houston to study life-threatening vulnerable plaques, the cause of at least two-thirds of all heart attacks, and new ways to prevent them.
The gift will underwrite two, three-year research positions for a Ph.D. student and a postdoctoral fellow assigned to the ongoing collaboration.
“We are very grateful for this important gift from the Farish Fund. It comes at a time when interest in computational medicine and particularly in modeling functions of the cardiovascular system are at an all-time high,” said J. Tinsley Oden, director of ICES and professor of mathematics, and aerospace engineering and engineering mechanics. “And we are excited for this gift’s part in building a strong collaboration between ICES and a leading national heart center, the Texas Heart Institute.”
Dr. James T. Willerson, THI president and medical director, also expressed his thanks to the Farish family and foundation.
“Being able to detect vulnerable atherosclerotic plaques noninvasively and intervene before they rupture and cause heart attacks or strokes is important to everyone,” he said. “This support will help us in our quest to achieve that goal.”
Vulnerable plaques are fatty lipid pool deposits in the inner layer of the arterial wall. Unfortunately, standard medical imaging tests such as MRIs, CT scans, external ultrasound and coronary angiography fail to detect them because they often do not cause significant narrowing of the coronary artery. ICES Professor Thomas J.R. Hughes and ICES JTO Faculty Fellow and THI Research Scientist/ Assistant Professor Shaolie Hossain created a 3-D model of a heart drug delivery system that demonstrates how new patient-specific imagery and nanoparticles can be used to potentially detect vulnerable plaques and precisely deliver supplemental drugs tailored to each patient’s anatomy and physiology.
“Everybody hears about heart disease and heart attacks, yet vulnerable plaques are often the source — they are very insidious,” says Hughes, a professor of aerospace engineering and engineering mechanics.
New imaging technologies have yielded promising results. For example, virtual histology intravascular ultrasound (VH-IVUS) generates images of an artery cross section from an ultrasound catheter tracked through the vasculature. It can distinguish between low-risk artery wall thickening and a high-risk lesion. Once identified, current drugs such as statins prevent about 30 percent of vulnerable plaque heart attacks or strokes.
“Both detection and treatment of vulnerable plaques represent huge unmet clinical needs,” says Hughes. “If a vulnerable plaque ruptures and blocks flow to an area of the heart, it’s a heart attack; if it blocks an artery in the brain, it’s a stroke.”
New studies propose supplementing statins with drugs delivered directly to diseased arteries to rapidly stabilize vulnerable plaques and prevent rupture.
“Using this newly available information from a patient’s VH-IVUS, we can generate models showing the specific geometry of a patient’s arterial wall, as well as the fine junctures among arteries,” says Hossain. “The methodology will allow a physician to identify the location of the vulnerable plaque and inject a customized amount of the drug at a specific site tailored to the patient’s artery structure and blood flow features for the best outcome.”
“To model these very complicated systems takes millions of equations that need to be solved at each of millions of time steps, so the computational burden is enormous,” Hughes says.
The treatment represents a continuation of decades of work by Hughes and his students to develop effective patient-specific heart disease interventions.
Pre-clinical validation of the methodology is the next step.
“This will take us closer to the clinical work to help develop new, noninvasive procedures for new drugs,” Hossain says.
For more information, contact: Becky Rische, Institute for Computational Engineering and Science, 512 471 4978; Frank Michel, Texas Heart Institute, email@example.com